Table 2 Summary of the studies reported on using Gabapentin as a medical line of CTS conservative management
Author | Study | Sample size | Intervention (mg) | Duration | Side effects | Conclusion |
|---|---|---|---|---|---|---|
Duman et al. [5] | Uncontrolled | 18 | • Gabapentin 600–900 | 3 months | 5 dizziness 2 headache 1 GIT | Gabapentin might have beneficial effects in the management of CTS in terms of clinical tests, VAS (pain/numbness/sleep), SSS, FSS, and patient’s global satisfaction. |
Taverner et al. [33] | Uncontrolled | 25 | • Gabapentin 300–1800 | 6 months | 4 dizziness 2 rash 1 GIT | Gabapentin was effective in the reduction of pain and improvement of the severity of the symptoms. |
Erdemoglu et al. [34] | Uncontrolled | 41 | • Gabapentin 600–3600 | 6 months | 8 GIT 3 dizziness | Gabapentin was found to be partially effective and safe in treatment of CTS patients in terms of SSS and FSS |
Hui et al. [8] | Randomized Double-blinded Controlled | 71/69 | • Gabapentin 300, then 600, then 900 • Placebo | 2 months | 28 dizziness 15 somnolence 10 fatigue 8 paresthesia 8 headache 7 GIT | The mean reduction in symptom severity in the gabapentin was not significant when compared with placebo in terms of GSS |
Sabet et al. [35] | Randomized Double-blinded Controlled | 25/25 | • Naproxen 500 • Naproxen 500 + Gabapentin 100 then 300 | 2 months | – | Combination of gabapentin and naproxen is significantly associated with SSS and FSS reduction than administration of naproxen alone |
Sabet et al. [36] | Controlled | 25/25 | • Naproxen 500 • Naproxen 500 + Gabapentin 100 then 300 | 2 months | – | Gabapentin improved the SNCV and DML |